Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review

Natalizumab, a monoclonal antibody acting on alpha4 integrin receptors, is frequently used to treat multiple sclerosis patients. The biggest downside is the risk of development of progressive multifocal leukoencephalopathy, an immune-related condition affecting mainly the central nervous system. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Vivekanandan, Govinathan, Abubacker, Ansha P, Myneni, Revathi, Chawla, Harsh V, Iqbal, Aimen, Grewal, Amit, Ndakotsu, Andrew, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169000/
https://www.ncbi.nlm.nih.gov/pubmed/34094729
http://dx.doi.org/10.7759/cureus.14764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169000/
https://www.ncbi.nlm.nih.gov/pubmed/34094729
http://dx.doi.org/10.7759/cureus.14764

Ejemplares similares